Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Retrieved on: 2021-02-25 18:45:00

Tags for this article:

Click the tags to see associated articles and topics

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. View article details on hiswai:

Excerpt

Remdesivir (12, 13) and dexamethasone (14) have each improved patient outcomes in clinical trials and have been approved for emergency use by ...

Article found on: science.sciencemag.org